Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7421629 | 1.00 | TSHR (0.41) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL3876359 | 1.00 | TSHR (0.41) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL1133379 | 0.85 | GRIK1 (0.46) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL8596279 | 0.85 | GRIK1 (0.37) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL2361609 | 0.80 | GRIK1 (0.34) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL2361611 | 0.80 | GRIK1 (0.34) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL23688391 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1TDP1 | |
| SCHEMBL8020514 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1TDP1 | |
| SCHEMBL6530499 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1TDP1 | |
| SCHEMBL8017237 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3688175-B1 | GENETICALLY MODIFIED ISOPROPYLMALATE ISOMERASE ENZYME COMPLEXES AND PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C5-C10 COMPOUNDS THEREWITH | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11898181-B2 | Genetically modified isopropylmalate isomerase enzyme complexes and processes to prepare elongated 2-ketoacids and C5-C10 compounds therewith | DOW GLOBAL TECHNOLOGIES LLC | 2024-02-13 | — | — | US | disclosed |
| US-11236310-B2 | Process to prepare elongated 2-ketoacids and C-5-C10 compounds therefrom via genetic modifications to microbial metabolic pathways | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-11230705-B2 | Genetically modified isopropylmalate isomerase enzyme complexes and processes to prepare elongated 2-ketoacids and C5-C10 compounds therewith | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-10995322-B2 | Processes to prepare elongated 2-ketoacids and C5-C10 compounds therefrom via genetic modifications to microbial metabolic pathways | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200291378-A1 | GENETICALLY MODIFIED ISOPROPYLMALATE ISOMERASE ENZYME COMPLEXES AND PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C5-C10 COMPOUNDS THEREWITH | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3688175-A1 | GENETICALLY MODIFIED ISOPROPYLMALATE ISOMERASE ENZYME COMPLEXES AND PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C5-C10 COMPOUNDS THEREWITH | Dow Global Technologies LLC (US) | 2020-08-05 | — | — | EP | disclosed |
| CN-111201321-A | Genetically modified isopropylmalate isomerase complex and method for preparing elongated 2-keto acids and C using same5-C10Method for preparing compounds | 陶氏环球技术有限责任公司 | 2020-05-26 | — | — | CN | disclosed |
| US-20190316158-A1 | PROCESS TO PREPARE ELONGATED 2-KETOACIDS AND C-5-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-10-17 | — | — | US | disclosed |
| EP-3532624-A1 | PROCESS TO PREPARE ELONGATED 2-KETOACIDS AND C5-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | Dow Global Technologies LLC (US) | 2019-09-04 | — | — | EP | disclosed |
| CN-105793431-A | Processes to prepare elongated 2-ketoacids and c6-c10 compounds therefrom via genetic modifications to microbial metabolic pathways | 陶氏环球技术有限责任公司 | 2016-07-20 | — | — | CN | disclosed |
| WO-2015089127-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8911717-B2 | Polymalic acid-based multifunctional drug delivery system | CEDARS-SINAI MEDICAL CENTER (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140039125-A1 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM | ARROGENE NANOTECHNOLOGY, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8562964-B2 | Polymalic acid-based multifunctional drug delivery system | CEDARS-SINAI MEDICAL CENTER (US) | 2013-10-22 | — | — | US | disclosed |
| US-20110212048-A1 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM | CEDARS-SINAI MEDICAL CENTER (US) | 2011-09-01 | — | — | US | disclosed |
| US-7935677-B2 | Polymalic acid-based multi-functional drug delivery system | CEDARS-SINAI MEDICAL CENTER (US) | 2011-05-03 | — | — | US | disclosed |
| US-20070259008-A1 | Polymalic Acid-Based Multi-Functional Drug Delivery System | ARROGENE, INC. | 2007-11-08 | — | — | US | disclosed |
| EP-1689443-A2 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM | ARROGENE, INC. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005055980-A2 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM | ARROGENE, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039125-A1 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM | PACSIN2, ERBB2, ERBB3 | TSHR 3432/4885GRIK1 989/4885GRIK2 463/4885 |
| US-20110212048-A1 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM | SLC43A1, HACD3, HACD2 | TSHR 4050/4885GRIK1 2716/4885GRIK2 1934/4885 |
| US-20070259008-A1 | Polymalic Acid-Based Multi-Functional Drug Delivery System | SLC43A1, HACD2, HACD3 | TSHR 3754/4885GRIK1 2761/4885GRIK2 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.